Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by dmacdon Mar 26, 2019 1:55pm
66 Views
Post# 29537930

RE:RE:RE:China News...

RE:RE:RE:China News...Hi Ingi. I am an armchair investor as well. We have an easy role and are known for our impatience. Ha Ha. I wonder if Replicel has another partner in mind to show Shiseido that if they do not move then someone else will. I prefer Shiseido but if they are being difficult then time to move the bishop or knight into play. It is a bit of a dysfunctional chess match at the moment but they are still at the table. It certainly sends a message to Shiseido either directly or indirectly. Time will tell and perhaps even Replicel may not yet know that answer. YOFOTO is very promising and remember that they own a good chuck of Replicel and may yet buy us out which again would go badly for Shiseido if they are interested in controlling the Japanese market and beyond. Competition is a good thing for sure. Much better days may be ahead looking out 2 or 3 years though. I will continue to hold with that expectation. It was always a 3 to 5 year hold for me but I only got in about a year and half ago and while it has not performed to all my expectations I see potential for the goals to be fulfilled with in a very challenging finanical market for these med techs. 

Cheers


Bullboard Posts